The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that therapeutic responses may be improved via its modulation (13, 14)”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [14]
In the citing paper
“The P-ESC was considered representative of baseline microbiome data due to observations that the microbiome of patients treated with anti-PD-1, unlike anti-CTLA-4 or chemotherapy, is stable early after therapy initiation17–19.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [19]
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [26]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 2×
“Finally, monoassociation of tumor-bearing GF mice with SFB, which promotes Th17 cell differentiation in the LP (1, 13, 14) also had a detrimental impact on the tumor growthinhibitory effect of CTX (Fig.”
BackgroundImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Some antineoplastic agents mediate part of their anticancer activity by stimulating anticancer immune responses (6).”
BackgroundSelf-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“S6A) and is required for the therapeutic success of anticancer chemotherapies in several tumor models (19).”
BackgroundSelf-citationInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Self-citation
Research works printed but not linked: 1
- 10.1073/pnas.1113744109 · DOI · Paper page
Cited by
Items 201–300 of 1,012
Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors
Montalban-Arques, A., Katkeviciute, E., Busenhart, P., Bircher, A., Wirbel, J., Zeller, G., Morsy, Y., Borsig, L., Glaus Garzon, J. F., Müller, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.08.001 · Cited by 197
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives
Badgeley, A., Anwar, H., Modi, K., Murphy, P., & Lakshmikuttyamma, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188494 · Cited by 196
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Barrea, L., Muscogiuri, G., Frias-Toral, E., Laudisio, D., Pugliese, G., Castellucci, B., Garcia-Velasquez, E., Savastano, S., & Colao, A. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1792826 · Cited by 195
Fusobacterium nucleatum and cancer
Alon‐Maimon, T., Mandelboim, O., & Bachrach, G. (2022) · Periodontology 2000 · doi:10.1111/prd.12426 · Cited by 194
Song, W., Tiruthani, K., Wang, Y., Shen, L., Hu, M., Dorosheva, O., Qiu, K., Kinghorn, K. A., Liu, R., & Huang, L. (2018) · Advanced Materials · doi:10.1002/adma.201805007 · Cited by 194
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
Gut Microbiota Shapes the Efficiency of Cancer Therapy
Ma, W., Mao, Q., Xia, W., Dong, G., Yu, C., & Jiang, F. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01050 · Cited by 192
Understanding the role of the gut microbiome in gastrointestinal cancer: A review
Ağagündüz, D., Cocozza, E., Cemali, Ö., Bayazıt, A. D., Nanì, M. F., Cerqua, I., Morgillo, F., Saygılı, S. K., Berni Canani, R., Amero, P., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1130562 · Cited by 189
Lévy, J., Cacheux, W., Bara, M. A., L’Hermitte, A., Lepage, P., Fraudeau, M., Trentesaux, C., Lemarchand, J., Durand, A., Crain, A.-M., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3206 · Cited by 189
Self-citationOn‐Demand Bacterial Reactivation by Restraining within a Triggerable Nanocoating
Feng, P., Cao, Z., Wang, X., Li, J., & Liu, J. (2020) · Advanced Materials · doi:10.1002/adma.202002406 · Cited by 189
Low dose cyclophosphamide: Mechanisms of T cell modulation
Madondo, M. T., Quinn, M., & Plebanski, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.005 · Cited by 188
Galloway‐Peña, J. R., Smith, D. P., Sahasrabhojane, P., Ajami, N. J., Wadsworth, W. D., Daver, N. G., Chemaly, R. F., Marsh, L., Ghantoji, S. S., Pemmaraju, N., et al. (2016) · Cancer · doi:10.1002/cncr.30039 · Cited by 188
Goodman, B., & Gardner, H. (2018) · The Journal of Pathology · doi:10.1002/path.5047 · Cited by 187
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Tang, C., Sun, J., Zhou, B., Jin, C., Liu, J., Kan, J., Qian, C., & Zhang, N. (2018) · Food & Function · doi:10.1039/c7fo01302g · Cited by 186
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., De Cecco, L., Fasano, E., Bianchi, F., Bertolotti, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1659 · Cited by 184
Commensal bacteria stimulate antitumor responses via T cell cross-reactivity
Bessell, C. A., Isser, A., Havel, J. J., Lee, S., Bell, D. R., Hickey, J. W., Chaisawangwong, W., Glick Bieler, J., Srivastava, R., Kuo, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135597 · Cited by 184
Radiotherapy and the gut microbiome: facts and fiction
Liu, J., Liu, C., & Yue, J. (2021) · Radiation Oncology · doi:10.1186/s13014-020-01735-9 · Cited by 183
Effects of cyclophosphamide on immune system and gut microbiota in mice
Xu, X., & Zhang, X. (2015) · Microbiological Research · doi:10.1016/j.micres.2014.11.002 · Cited by 183
New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 183
The Microbiome and Genitourinary Cancer: A Collaborative Review
Markowski, M. C., Boorjian, S. A., Burton, J. P., Hahn, N. M., Ingersoll, M. A., Maleki Vareki, S., Pal, S. K., & Sfanos, K. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.043 · Cited by 182
The intestinal microbiome and health
Tuddenham, S., & Sears, C. L. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000196 · Cited by 180
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
“Bacteria-specific immune response not only produces inflammation in intestinal mucous, but also promotes differentiation of pTh17 and Th1 in secondary immune organs [31, 78].”
BackgroundDysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases
Toor, D., Wsson, M. K., Kumar, P., Karthikeyan, G., Kaushik, N. K., Goel, C., Singh, S., Kumar, A., & Prakash, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102432 · Cited by 177
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94952 · Cited by 175
“Importantly, they demonstrated that only a specific phenotype of T cells, pathogenic and not naive Th17 T cells, could restore the CTX efficacy when administrated with vancomycin.”
BackgroundResultInfluentialImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
“Amongst other conventional chemotherapeutics, the following molecules directly stimulate the effector activity of myeloid of lymphoid cells: cyclophosphamide (an alkylating agent approved for the treatment of hematologic and solid neoplasms), which favored TH17 and TH1 memory responses, NK-cell and CD8 þ DC expansion…”
BackgroundSelf-citationPredictable modulation of cancer treatment outcomes by the gut microbiota
(2020) · doi:10.1186/s40168-020-00811-2 · Cited by 175
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00784-1 · Cited by 172
“Mice were treated with CTX or PBS, then randomly assigned to +/− cohousing with humanized mice with HV or BC.”
BackgroundInfluentialSelf-citationShi, H., Chang, Y., Gao, Y., Wang, X., Chen, X., Wang, Y., Xue, C., & Tang, Q. (2017) · Food & Function · doi:10.1039/c7fo00932a · Cited by 172
Ahmed, J., Kumar, A., Parikh, K., Anwar, A., Knoll, B. M., Puccio, C., Chun, H., Fanucchi, M., & Lim, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1507670 · Cited by 171
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Self-citationUtilization of the microbiome in personalized medicine
Ratiner, K., Ciocan, D., Abdeen, S. K., & Elinav, E. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00998-9 · Cited by 170
Metabolic programming in dendritic cells tailors immune responses and homeostasis
Møller, S. H., Wang, L., & Ho, P.-C. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00753-1 · Cited by 169
The Gut Microbiome and Sex Hormone-Related Diseases
He, S., Li, H., Yu, Z., Zhang, F., Liang, S., Liu, H., Chen, H., & Lü, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.711137 · Cited by 169
Pancreatic Cancer, Inflammation, and Microbiome
Zambirinis, C. P., Pushalkar, S., Saxena, D., & Miller, G. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000045 · Cited by 169
Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases
Chehimi, M., Vidal, H., & Eljaafari, A. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6070068 · Cited by 166
Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
Lee, Y., Kamada, N., & Moon, J. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114021 · Cited by 165
Host Immune Response to Infection and Cancer: Unexpected Commonalities
Goldszmid, R. S., Dzutsev, A., & Trinchieri, G. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.003 · Cited by 165
The Fire Within: Microbes Inflame Tumors
Gagliani, N., Hu, B., Huber, S., Elinav, E., & Flavell, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.006 · Cited by 165
Tumour metabolism and its unique properties in prostate adenocarcinoma
Bader, D. A., & McGuire, S. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0288-x · Cited by 179
Rizvi, Z. A., Dalal, R., Sadhu, S., Kumar, Y., Kumar, S., Gupta, S. K., Tripathy, M. R., Rathore, D. K., & Awasthi, A. (2021) · Science Advances · doi:10.1126/sciadv.abg5016 · Cited by 157
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 178
Song, W., Wang, Y., Li, G., Xue, S., Zhang, G., Dang, Y., & Wang, H. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2276814 · Cited by 165
Gori, S., Inno, A., Belluomini, L., Bocus, P., Bisoffi, Z., Russo, A., & Arcaro, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.003 · Cited by 165
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
ElRakaiby, M., Dutilh, B. E., Rizkallah, M. R., Boleij, A., Cole, J. N., & Aziz, R. K. (2014) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2014.0018 · Cited by 164
Bao, Y., Tang, J., Qian, Y., Sun, T., Chen, H., Chen, Z., Sun, D., Zhong, M., Chen, H., Hong, J., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1925-2 · Cited by 164
Psychotropics and the Microbiome: a Chamber of Secrets…
Cussotto, S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5185-8 · Cited by 163
Gut microbiota: A new insight into lung diseases
Ma, P.-J., Wang, M.-M., & Wang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113810 · Cited by 163
Gaines, S., Shao, C., Hyman, N., & Alverdy, J. C. (2018) · British Journal of Surgery · doi:10.1002/bjs.10760 · Cited by 163
Sári, Z., Mikó, E., Kovàcs, T., Jankó, L., Csonka, T., Lente, G., Sebő, É., Tóth, J., Tóth, D., Árkosy, P., et al. (2020) · Cancers · doi:10.3390/cancers12092411 · Cited by 169
Harnessing non-destructive 3D pathology
Liu, J. T. C., Glaser, A. K., Bera, K., True, L. D., Reder, N. P., Eliceiri, K. W., & Madabhushi, A. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00681-x · Cited by 163
Grajeda-Iglesias, C., Durand, S., Daillère, R., Iribarren, K., Lemaitre, F., Derosa, L., Aprahamian, F., Bossut, N., Nirmalathasan, N., Madeo, F., et al. (2021) · Aging · doi:10.18632/aging.202739 · Cited by 161
“These species were selected because they improve the anticancer effects of cycloheximide-based chemotherapy, as true for Burkholderia cepacia (Brc) and Enterococcus hirae (Hir) [21, 22].”
Self-citationTrial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 150
Self-citationNutritional regulation of microbiota-derived metabolites: Implications for immunity and inflammation
Arifuzzaman, M., Collins, N., Guo, C., & Artis, D. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.009 · Cited by 169
Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities
Pandey, H., Tang, D. W. T., Wong, S. H., & Lal, D. (2023) · Cancers · doi:10.3390/cancers15030866 · Cited by 159
Fiebiger, U., Bereswill, S., & Heimesaat, M. M. (2016) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2016.00036 · Cited by 159
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
Tweak to Treat: Reprograming Bacteria for Cancer Treatment
Sieow, B. F.-L., Wun, K. S., Yong, W. P., Hwang, I. Y., & Chang, M. W. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.11.004 · Cited by 158
Voorde, J. V., Sabuncuoğlu, S., Noppen, S., Hofer, A., Ranjbarian, F., Fieuws, S., Balzarini, J. M., & Liekens, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558924 · Cited by 165
Linking Gut Microbiota to Colorectal Cancer
Raskov, H., Burcharth, J., & Pommergaard, H.-C. (2017) · Journal of Cancer · doi:10.7150/jca.20497 · Cited by 146
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 152
Role of gut microbiota in liver disease
Albhaisi, S. A. M., Bajaj, J. S., & Sanyal, A. J. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00118.2019 · Cited by 164
Vernocchi, P., Gili, T., Conte, F., Del Chierico, F., Conta, G., Miccheli, A., Botticelli, A., Paci, P., Caldarelli, G., Nuti, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228730 · Cited by 148
Lenoir, M., del Carmen, S., Cortes-Perez, N. G., Lozano-Ojalvo, D., Muñoz-Provencio, D., Chain, F., Langella, P., de Moreno de LeBlanc, A., LeBlanc, J. G., & Bermúdez-Humarán, L. G. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-015-1158-9 · Cited by 155
“Currently, some studies have demonstrated that both probiotic bacteria and gut microbiota [2] could be an alternative approach to prevent and treat a number of human diseases including cancer and CRC [3, 4].”
BackgroundRetractedHallmarks of Resistance to Immune-Checkpoint Inhibitors
Karasarides, M., Cogdill, A. P., Robbins, P. B., Bowden, M., Burton, E. M., Butterfield, L. H., Cesano, A., Hammer, C., Haymaker, C., Horak, C. E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0586 · Cited by 160
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Kunisada, Y., Eikawa, S., Tomonobu, N., Domae, S., Uehara, T., Hori, S., Furusawa, Y., Hase, K., Sasaki, A., & Udono, H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.009 · Cited by 149
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Sfanos, K. S., Markowski, M. C., Peiffer, L. B., Ernst, S. E., White, J. R., Pienta, K. J., Antonarakis, E. S., & Ross, A. E. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0061-x · Cited by 147
Dietary astaxanthin: an excellent carotenoid with multiple health benefits
Cao, Y., Yang, L., Qiao, X., Xue, C., & Xu, J. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1983766 · Cited by 155
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
Renga, G., Nunzi, E., Pariano, M., Puccetti, M., Bellet, M. M., Pieraccini, G., D’Onofrio, F., Santarelli, I., Stincardini, C., Aversa, F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003725 · Cited by 156
Dexosomes as a cell-free vaccine for cancer immunotherapy
Nikfarjam, S., Rezaie, J., Kashanchi, F., & Jafari, R. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01781-x · Cited by 157
Wang, L., Lynch, C. M., Pitroda, S. P., Piffkó, A., Yang, K., Huser, A. K., Liang, H. L., & Weichselbaum, R. R. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232101 · Cited by 155
Anticancer metal drugs and immunogenic cell death
Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 151
Xu, L., Zhang, Y., Li, X., Li, C., Hu, H., Hu, J., Liu, M., Yang, Q. Z., Gu, P., Li, J., et al. (2025) · iMeta · doi:10.1002/imt2.270 · Cited by 154
Chase, D. M., Goulder, A., Zenhausern, F., Monk, B. J., & Herbst‐Kralovetz, M. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.036 · Cited by 164
The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.
Enright, E. F., Gahan, C. G. M., Joyce, S. A., & Griffin, B. T. (2016) · PubMed · Cited by 202
Microbiome dysbiosis in lung cancer: from composition to therapy
Liu, N., Ma, Q., Ge, Y., Yi, C., Wei, L., Tan, J.-C., Chu, Q., Li, J., Zhang, P., & Wang, H. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00138-z · Cited by 156
Increased gut permeability in cancer cachexia: mechanisms and clinical relevance
Bindels, L. B., Neyrinck, A. M., Loumaye, A., Catry, E., Walgrave, H., Cherbuy, C., Leclercq, S., Van Hul, M., Plovier, H., Pachikian, B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24804 · Cited by 147
“For instance, gut barrier alterations induced by cyclophosphamide is essential for the efficacy of the drug [49].”
BackgroundMicrobial markers in colorectal cancer detection and/or prognosis
Villéger, R., Lopès, A., Véziant, J., Gagnière, J., Barnich, N., Billard, E., Boucher, D., & Bonnet, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2327 · Cited by 158
The microbiome and breast cancer: a review
Chen, J. H., Douglass, J., Prasath, V., Neace, M., Atrchian, S., Manjili, M. H., Shokouhi, S., & Habibi, M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05407-5 · Cited by 156
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview
Ivanova, E. A., & Orekhov, A. N. (2015) · BioMed Research International · doi:10.1155/2015/327470 · Cited by 166
Fischer, J. C., Bscheider, M., Eisenkolb, G., Lin, C.-C., Wintges, A., Otten, V., Lindemans, C. A., Heidegger, S., Rudelius, M., Monette, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2513 · Cited by 142
Carcinogenesis and therapeutics: the microbiota perspective
Tsilimigras, M. C. B., Fodor, A., & Jobin, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.8 · Cited by 144
Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 152
Zhu, Z., Cai, J., Hou, W., Xu, K., Wu, X., Song, Y., Bai, C., Mo, Y.-Y., & Zhang, Z. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2166700 · Cited by 133
Abdollahi‐Roodsaz, S., Abramson, S. B., & Scher, J. U. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.68 · Cited by 150
The microbiome and cancer for clinicians
Picardo, S. L., Coburn, B. A., & Hansen, A. R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.004 · Cited by 150
Oral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling
McVey Neufeld, K.-A., Bienenstock, J., Bharwani, A., Champagne-Jorgensen, K., Mao, Y., West, C., Liu, Y., Surette, M. G., Kunze, W., & Forsythe, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-50807-8 · Cited by 132
Microbiota, NASH, HCC and the potential role of probiotics
Brandi, G., De Lorenzo, S., Candela, M., Pantaleo, M. A., Bellentani, S., Tovoli, F., Saccoccio, G., & Biasco, G. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx007 · Cited by 142
Gebremeskel, S., & Johnston, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6113 · Cited by 149
The Microbiome as a Component of the Tumor Microenvironment
Kovàcs, T., Mikó, E., Ujlaki, G., Sári, Z., & Bai, P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35727-6_10 · Cited by 140
Ashrafizadeh, M., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Bagherian, M., Azami, N., Bejandi, A. K., Hushmandi, K., Ang, H. L., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111084 · Cited by 134
Precision medicine using microbiota
Jobin, C. (2018) · Science · doi:10.1126/science.aar2946 · Cited by 133
Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs
Feng, W., Liu, J., Ao, H., Yue, S., & Peng, C. (2020) · Theranostics · doi:10.7150/thno.47289 · Cited by 121
Metadata
- Authors
- Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C. O., Doré, J., Kroemer, G., Lepage, P., Boneca, I. G., Ghiringhelli, F., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Agency for Science, Technology and Research (SG)
- Institut National de la Santé et de la Recherche Médicale, U866, Centre Georges François Leclerc, Dijon, France.
- Service de Microbiologie, Institut Gustave Roussy, Villejuif, France.
- Institut Gustave Roussy (FR)
- Institut Pasteur (FR)
- Nimalerie Centrale, Institut Pasteur, Paris, France.
- Institut National de la Recherche Agronomique, Micalis–UMR1319, 78350 Jouy-en-Josas, France.
- Centre National de la Recherche Scientifique (FR)
- Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, Marseille, France.
- Université d'Orléans (FR)
- University of Alabama at Birmingham (US)
- AgroParisTech (FR)
- Corresponding author
- Ghiringhelli, François
- Zitvogel, Laurence
- ORCID
- Mignot, Grégoire
- Yamazaki, Takahiro
- Daillère, Romain
- Hannani, Dalil
- Pfirschke, Christina
- Engblom, Camilla
- Schlitzer, Andreas
- Ginhoux, Florent
- Woerther, Paul-Louis
- Eberl, Gérard
- Clermont, Dominique
- Opolon, Paule
- Ryffel, Bernhard
- Elson, Charles O.
- Kroemer, Guido
- Lepage, Patricia
- Boneca, Ivo Gomperts
- Ghiringhelli, François
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 971-976
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4048947
- OpenAlex
- W2059128083
- Cited by
- 2,050
- References
- 43
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 176 · 2023: 216 · 2022: 234 · 2021: 217 · 2020: 220 · 2019: 183 · 2018: 137 · 2017: 116 · 2016: 98 · 2015: 101 · 2014: 69 · 2013: 6
- FWCI
- 40.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- HAL AMU (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-11-PHUC-0002)
- National Cancer Institute (P50CA086355)
- National Institute of Allergy and Infectious Diseases (R01AI084880)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK071176)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cyclophosphamide, gut microbiota, antitumor immunity, Gram-positive bacteria, Th17 cells, memory T cells, secondary lymphoid organs, bacterial translocation, germ-free mice, antibiotic therapy, adoptive transfer, small intestine
- MeSH terms
- Animals, Anti-Bacterial Agents, Antineoplastic Agents, Cyclophosphamide, Germ-Free Life, Gram-Positive Bacteria, Immunologic Memory, Immunosuppressive Agents, Intestine, Small, Lymphoid Tissue, Neoplasms, Bacterial Translocation, Adoptive Transfer, Mice, Th17 Cells, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.